Approval · Notice of Compliance 11007 · 2010
GABAPENTIN: Notice of Compliance 11007
Issued February 5, 2010
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 11007
- Date
- February 5, 2010
- Company
- Cobalt Pharmaceuticals IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Additional product name
- Therapeutic class
- Antiepileptic agent
- Canadian reference product
- NEURONTIN
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| GABAPENTIN | 02342650 | Cancelled Pre Market |
| GABAPENTIN | 02342669 | Cancelled Pre Market |
| GABAPENTIN | 02342677 | Cancelled Pre Market |
Medicinal ingredients
- GABAPENTIN 100 MG per CAP
- GABAPENTIN 300 MG per CAP
- GABAPENTIN 400 MG per CAP